

NYRx Notice to Pharmacies: Gabapentin

May 1, 2025

NYRx, the Medicaid pharmacy program, is sharing this notice with pharmacies to inform them of important therapeutic duplication information when submitting claims for gabapentin:

- NYRx covers medically necessary, FDA-approved drugs when prescribed according to the FDA-approved package label, compendia-supported use, or aligned with peer-reviewed clinical practice guidelines.
- NYRx does not cover more than one strength or formulation of gabapentin at a time. To reduce overutilization, stockpiling, and/or diversion of drugs, pharmacies will receive a rejection when submitting claims for more than one strength or formulation of gabapentin while the patient still has greater than a 7-day supply of their current fill remaining.

Note: If a prescriber determines the patient's treatment regimen requires multiple different daily doses or formulations, or there is a need to switch the dose or formulation while the patient still has greater than a 7-day supply of a current fill remaining, the prescriber may request a prior authorization from the NYRx Clinical Call Center.

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.